Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

被引：0
作者：
Lan-Lan Pang
Jia-Di Gan
Yi-Hua Huang
Jun Liao
Wei-Tao Zhuang
Wael-Abdullah-Sultan Ali
Shao-Dong Hong
Li Zhang
Wen-Feng Fang
机构：
[1] Sun Yat-Sen University Cancer Center,Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
来源：
BMC Cancer | / 23卷
关键词：
Non-small cell lung cancer; Immunotherapy; Chemotherapy; Combination; Antiangiogenic agents; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials
    Ponvilawan, B.
    Sharma, P.
    Mahadevia, H.
    Qasim, H.
    Subramanian, J.
    Bansal, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S627 - S627
  • [22] Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC
    El-Ghazzi, Nathan
    Lavaud, Pernelle
    BULLETIN DU CANCER, 2021, 108 (03) : 231 - 233
  • [23] Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
    Jin, Xuanhong
    Pan, Yang
    Cheng, Cheng
    Shen, Hangchen
    Zhai, Chongya
    Yin, Kailai
    Zhu, Xinyu
    Pan, Hongming
    You, Liangkun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [24] Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis
    Guven, Deniz Can
    Stephen, Bettzy
    Sahin, Taha Koray
    Cakir, Ibrahim Yahya
    Aksoy, Sercan
    LARYNGOSCOPE, 2024, 134 (01) : 7 - 17
  • [25] Treatment-Related Adverse Events in Patients with Advanced NSCLC Treated with First-Line Atezolizumab Chemoimmunotherapy
    Swarup, S.
    Thein, K.
    Sultan, A.
    Jahan, N.
    Quirch, M.
    Meda, S.
    Htut, T.
    Adhikari, N.
    Hlaing, P.
    Dash, A.
    Tun, A.
    Rehman, S.
    Hardwicke, F.
    Tijani, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S390 - S390
  • [26] Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC
    Gao, Zhiqiang
    Han, Baohui
    Wang, Huimin
    Shi, Chunlei
    Xiong, Liwen
    Gu, Aiqin
    ONCOLOGY LETTERS, 2012, 3 (05) : 1064 - 1068
  • [27] Real World Efficacy of First-Line Immunotherapy plus /Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics
    Akerley, W.
    Halawani, H.
    Schaefer, E.
    Page, R.
    Ghabach, B.
    Evans, J.
    Shunyakov, L.
    Oubre, D.
    Veatch, A.
    Akulian, J.
    Velcheti, V.
    Pitcher, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S325 - S325
  • [28] Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
    Ren, Shengxiang
    Chen, Jianhua
    Xu, Xingxiang
    Jiang, Tao
    Cheng, Ying
    Chen, Gongyan
    Pan, Yueyin
    Fang, Yong
    Wang, Qiming
    Huang, Yunchao
    Yao, Wenxiu
    Wang, Rui
    Li, Xingya
    Zhang, Wei
    Zhang, Yanjun
    Hu, Sheng
    Guo, Renhua
    Shi, Jianhua
    Wang, Zhiwu
    Cao, Peiguo
    Wang, Donglin
    Fang, Jian
    Luo, Hui
    Geng, Yi
    Xing, Chunyan
    Lv, Dongqing
    Zhang, Yiping
    Yu, Junyan
    Cang, Shundong
    Yang, Zeyu
    Shi, Wei
    Zou, Jianjun
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 544 - 557
  • [29] A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
    Qu, Jialin
    Wang, Li
    Jiang, Man
    Zhao, Deze
    Wang, Yuyang
    Zhang, Feng
    Li, Jing
    Zhang, Xiaochun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6493 - 6509
  • [30] The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer
    Rocco, Danilo
    Della Gravara, Luigi
    Battiloro, Ciro
    Gridelli, Cesare
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (03) : 303 - 309
12345